AUROBINDO TO MARKET GENERIC HIV DRUGS IN BOTSWANA

Aurobindo Pharma has successfully registered nine generic antiretroviral (ARV) drugs in Botswana, The Hindu Business Line reports.

Botswana's Drugs Regulatory Unit has accepted registrations for lamivudine-zidovudine combination tablets, nevirapine tablets (200 mg), tavudine capsules (30 mg), stavudine capsules (40 mg), lamivudine tablets (150 and 300 mg), zidovudine oral solution (50 mg/5 mL), nevirapine oral suspension (50 mg/mL) and lamivudine oral solution (10 mg/mL), according to the article in Business Line. The drugs are for treating HIV.

The Indian drugmaker also recently received South African Medicines Control Council (MCC) approval for generic lisinopril, a cardiovascular drug. Previously the company won MCC approval for several generic ARVs, including stavudine, lamivudine and nevirapine, along with combination tablets.